Frontlight ResearchEarly access
Active, not recruitingNo phase
Safety and Efficacy of the Surpass Evolve Flow Diverter in Treating Intracranial Aneurysms
Key facts
- Who runs it
- Yibin Fang
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 150 people, planned
- Started
- 29 Nov 2024
- Ended
- 31 Dec 2025
- Type of study
- Observational
- Treatments tested
- Flow diverting
- Record updated
- 13 December 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Age ≥ 18 years with a confirmed diagnosis of intracranial aneurysm
- Imaging studies confirming suitability for Surpass Evolve Flow Diverter treatment
- Aneurysms meeting flow diverter treatment indications (e.g., aneurysms larger than 4 mm)
- At least six months of follow-up data available post-treatment
Who cannot take part
- Patients with acutely ruptured aneurysms or significant bleeding
- Patients with incomplete data or insufficient follow-up records
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Safety and Efficacy of the Surpass Evolve Flow Diverter in Treating Intracranial Aneurysms
The group in the trial
- Surpass Evolve Flow Diverter
Treatment: Flow diverting
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 13 December 2024